Dusquetide, the active ingredient in SGX945 (Behçet's Disease) and SGX942 (oral mucositis), is an innate defense regulator ...

The report provides a comprehensive analysis of the global chemotherapy-induced oral mucositis market, highlighting key trends, drivers, and challenges shaping the industry. The estimated to secure a ...

Soligenix, Inc. (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical ...

This finding confirms previous observations from more intensive treatments, the study authors noted. To explore the possible association of intestinal mucositis with bloodstream infections and ...

Study DUS-AUBD-01 opens patient enrollment PRINCETON, N.J., Nov. 14, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage ...

(NASDAQ:JAGX) ("Jaguar") today announced that Jaguar family company Napo Pharmaceuticals ("Napo") has initiated the commercial launch of the FDA-approved oral mucositis prescription product ...

Oropharyngeal mucositis is an acute and distressing toxic effect of chemotherapy and head and neck irradiation. This oral sequela significantly impairs the daily functioning and quality of life of ...

SAN FRANCISCO, CA / ACCESSWIRE / October 16, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that Jaguar family company Napo Pharmaceuticals ("Napo") has initiated the commercial ...

SAN FRANCISCO, CA / ACCESSWIRE / October 16, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar”) today announced that Jaguar family company Napo Pharmaceuticals (“Napo”) has initiated the commercial ...

Sanara MedTech Inc (SMTI) achieves its 12th consecutive record revenue quarter, while navigating increased expenses and ...

T he stock of small-cap biotech Jaguar Health Inc. rose 7% on Wednesday, after the company launched its gelclair treatment for oral mucositis, a common side effect suffered by head and neck cancer ...

Jaguar Health Inc ( NASDAQ:JAGX) reported a 4% increase in net revenue for Q3 2024 compared to Q2 2024, and an 11% increase compared to Q3 2023. The company achieved significant results in a phase ...